Table 2.
Characteristics of acute rejection and graft failure within the first 3 months after transplantation for recipients stratified for donor-specific antibodies for HLA.
| No pretransplant DSA (n = 574) | Pretransplant DSA (n = 160) | pvalue | |
|---|---|---|---|
| Number of TCMR | 102 | 31 | 0.64 |
| Number of ABMR | 0 | 5 | 0.0005 |
| Total number of graft losses | 30 (5.2%) | 15 (9.4%) | 0.06 |
| Primary nonfunctioning graft | 18 (3.1%) | 12 (7.5%) | 0.02 |
| Causes of graft loss | |||
| Death with functioning graft | 8 (1.4%) | 2 (1.2%) | >0.99 |
| Vasculitis | 10 (1.7%) | 5 (3.1%) | 0.33 |
| Vasculitis with thrombi in arterioles | 1 (0.2%) | 3 (1.9%) | 0.03 |
| Vasculitis with tubulointerstitial rejection | 7 (1.2%) | 0 (0.0%) | 0.35 |
| Thrombi/TMA without vasculitis | 1/0 (0.2%) | 4/1 (3.1%) | 0.002 |
| Renal vein/artery thrombosis | 3/1 (0.7%) | 1 (0.6%) | >0.99 |
| Acute tubular necrosis | 2 (0.5%) | 1 (0.6%) | >0.99 |
| Others | 3 (0.5%) | 1 (0.6%) | >0.99 |
| Surgery-related complications | 2 (0.3%) | 0 (0.0%) | >0.99 |
DSA: donor-specific anti-HLA antibodies; TCMR: T cell-mediated rejection; ABMR: antibody-mediated rejection; TMA: thrombotic microangiopathy.